title: Adverse effects of inhaled budesonide (800 micrograms) on growth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration.
abstract: BACKGROUND
  Twice-daily administration of inhaled budesonide (400 micrograms) suppresses short-term growth in children with asthma.
  
  
  OBJECTIVE
  To compare short-term growth and markers of collagen turnover during treatment with 800 micrograms of inhaled budesonide administered once daily in the morning and 400 micrograms administered twice daily.
  
  
  METHODS
  Twenty-four children with asthma aged 5.6 to 12.5 years.
  
  
  METHODS
  An outpatient secondary referral center.
  
  
  METHODS
  A randomized, double-blind, crossover trial with 2 treatment periods of 4 weeks was conducted, and growth was assessed with a knemometer. The carboxy terminal propeptide of type I procollagen, the amino terminal propeptide of type I procollagen (PINP), the carboxy terminal pyridinoline cross-linked telopeptide of type I collagen, the amino terminal propeptide of type III procollagen (PIIINP), and urinary pyridinoline and deoxypyridinoline were evaluated.
  
  
  RESULTS
  Mean lower leg growth rate (P = .04), PINP (P = .03), and PIIINP (P < .01) were suppressed during twice-daily administration of budesonide, 400 micrograms. Otherwise, no statistically significant differences were detected.
  
  
  CONCLUSIONS
  As compared with 400 micrograms of inhaled budesonide administered twice daily, 800 micrograms administered once daily in the morning has a sparing effect on short-term growth and collagen turnover.
authors.affiliation: Department of Paediatrics, Aarhus University Hospital, Denmark.
authors.forename: C
authors.initials: C
authors.lastname: Heuck
authors.forename: O D
authors.initials: OD
authors.lastname: Wolthers
authors.forename: G
authors.initials: G
authors.lastname: Kollerup
authors.forename: M
authors.initials: M
authors.lastname: Hansen
authors.forename: B
authors.initials: B
authors.lastname: Teisner
mesh_terms: D000280:Administration, Inhalation; D000886:Anthropometry; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy*; D001827:Body Height / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003094:Collagen / Q000378:metabolism*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D019819:Budesonide; D003094:Collagen